간편하게 보는 뉴스는 유니콘뉴스
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia

· 등록일 Mar. 14, 2024 10:04

· 업데이트일 2024-03-15 20:55:21

OSAKA, JAPAN & CAMBRIDGE, MASS.--(Business Wire / Korea Newswire)--Takeda (TSE:4502/NYSE:TAK) today announced positive topline results from a Phase 2, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability and efficacy of mezagitamab (TAK-079) in patients with persistent or chronic primary immune thrombocytopenia (ITP). Mezagitamab is a fully human immunoglobulin IgG1 monoclonal antibody (mAb) with high affinity for CD38 expressing cells (including plasmablasts, plasma cells, natural killer cells) resulting in their depletion.

The TAK-079-1004 trial (NCT04278924) evaluated three different doses of subcutaneous mezagitamab vs placebo, given once weekly for eight weeks in patients with chronic (more than one year in duration) or persistent (3-12 months in duration) primary ITP. An interim analysis of the ongoing Phase 2 study demonstrated positive safety and efficacy results. Mezagitamab has been generally safe and well tolerated across all three cohorts. All mezagitamab doses tested demonstrated a higher platelet response rate than placebo. The increases in platelet count were dose-dependent with the greatest platelet response observed at the highest dose tested. Platelet response in mezagitamab treated patients occurred rapidly and was maintained post-therapy.

Based on these positive results, and following consultation with global health authorities, Takeda plans to initiate a global Phase 3 trial of mezagitamab in ITP in fiscal year 2024. When mezagitamab advances to Phase 3 in ITP Takeda will have five new molecular entities in Phase 3 development in fiscal year 2024 including TAK-279 for the treatment of psoriasis and psoriatic arthritis, TAK-861 for the treatment of narcolepsy type 1, soticlestat for the treatment of Lennox-Gastaut syndrome and Dravet syndrome, and fazirsiran for the treatment of α1-antitrypsin associated liver disease.

ITP is a rare, IgG mediated autoimmune disease caused, in part, by the development of autoantibodies to platelets (and/or megakaryocytes), which are blood cells responsible for preventing or stopping bleeding. ITP is characterized by the accelerated destruction of platelets (with or without impaired production), resulting in a decreased platelet count and an increased risk of bleeding, which can be debilitating (including fatigue and impaired quality of life), and in severe cases may be life-threatening. The precedent for approval of new drugs in this indication requires that platelet counts be maintained at 50,000/uL or more for a sustained period. Approximately 20 percent of patients with ITP do not achieve a platelet count above 50,000/uL following treatment with available first- and second-line therapies creating significant patient burden and unmet need for a disease modifying treatment that is also tolerable.[1,2]

“These Phase 2 results demonstrate mezagitamab’s compelling disease modifying mechanism of action, which has the potential to achieve disease remission for people with ITP. There remains considerable unmet need among ITP patients who may not respond or have inadequate response to prior treatment. In addition, some patients who do respond to available therapies struggle to manage side effects or relapse despite treatment,” said Chinwe Ukomadu, Head of the Gastrointestinal & Inflammation Therapeutic Area Unit at Takeda. “We look forward to initiating the Phase 3 trial and presenting these data at an upcoming scientific congress.”

Therapy with mezagitamab is designed to deliver rapid and sustained improvement in platelet response and generally rapidly restores platelet counts to functional levels. Mezagitamab previously received Orphan Drug Designation for the treatment of ITP from the U.S. Food and Drug Administration and the program recently received Fast Track Designation.

Results from the Phase 2 trial have no impact on the full year consolidated reported forecast for the fiscal year ending March 31, 2024 (Fiscal Year 2023).

About Takeda

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question-and-answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

Medical Information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

References

[1] Provan D, Donald A, et al. Blood Advances. 2019;26;3(22):3780-3817.
[2] Rodeghiero F. International Journal of Hematology. 2023;117:316-33.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240313160788/en/

Website: https://www.takeda.com/ Contact Takeda Pharmaceutical Company Limited
Japanese Media
Yuko Yoneyama
+81 70-2610-6609
[email protected]

U.S. and International Media
Chris Stamm
+1 617-374-7726
[email protected]
This news is a press release from the provider. Korea Newswire is committed to verifying the transparency of providers and eliminating content errors. You can receive press releases from this company or in industries of interest via email and RSS for free. Subscribe> News provided byTakeda Pharmaceutical Company Limited Distribution Channel Health Clinical Trials Pharmaceutical R&D Overseas
인기 기사12.23 20시 기준
서울--(뉴스와이어)--‘제13회 스웨덴영화제’(The 13th Swedish Film Festival)가 오는 9월 10일부터 29일까지 가을 한 달 동안의 개최 일정을 발표하고 공식 포스터를 공개했다. ‘제13회 스웨덴영화제’ 공식 포스터 ...
서울--(뉴스와이어)--사회복지법인 승가원(이사장 천원배)은 오는 5월 13일부터 제44회 장애인의 날을 기념해 ‘제3회 승가원 어린이 그림공모전’을 개최한다고 밝혔다. 2024년 장애인의 날 기념 제3회 승가원 어린이 그림공모전의 포스터...
스프링, 텍사스--(Business Wire / 뉴스와이어)--125년 이상 왁스 고객에게 서비스를 제공해 온 엑슨모빌(Exxon Mobil Corporation)이 새로운 제품 브랜드인 ‘프로왁스(Prowaxx™)’를 론칭하며 업계에 대한 헌신을 다시 한번 굳건히 했다. 새로운 아키텍처는 왁스 간 차별화 요소이며 4월 1일부터...
서울--(뉴스와이어)--IP와 생성 AI 관련 개발자 생태계 스토리(Story)가 9월 1일(일)부터 6일(금)까지 성수 스페이스 S1에서 ‘스토리 하우스(Story House)’를 개최한다고 밝혔다. 이 행사에서는 ‘Right Click: Remix’ 디지털 아트 전시와 더불어 AI (인공지능)와 IP (지식재산권)를 주제로 하는 콘퍼런스가...
ZUG, SWITZERLAND--(Business Wire / Korea Newswire)--Galderma today announced that full results from the phase III ARCADIA 1 and 2 clinical trials in atopic dermatitis were published in The Lancet.[1]The trials evaluated the efficacy and...
콘쇼호켄, 펜실베이니아--(Business Wire / 뉴스와이어)--지능형 통합 및 자동화 분야의 선두주자인 부미(Boomi™)는 오늘 부미의 의뢰를 받아 포레스터컨설팅(Forrester Consulting)에서 2023년 12월에 실시한 위탁 연구 결과를 발표했다. 이 연구에서 많은 기업들의 클라우드 지출이 통제되지 않거나 낭비가 심하며,...
API
fg
유니콘뉴스는 보도자료 배포 서비스입니다.
여기에 뉴스를 등록하면 언론이 보도하고 널리 배포됩니다.